Beddow Capital Management Inc. Has $8.40 Million Position in Johnson & Johnson (NYSE:JNJ)

Beddow Capital Management Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,830 shares of the company’s stock after acquiring an additional 1,290 shares during the quarter. Johnson & Johnson comprises 3.4% of Beddow Capital Management Inc.’s holdings, making the stock its 8th largest holding. Beddow Capital Management Inc.’s holdings in Johnson & Johnson were worth $8,400,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. First City Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 8.5% during the third quarter. First City Capital Management Inc. now owns 11,003 shares of the company’s stock valued at $1,783,000 after buying an additional 858 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its position in Johnson & Johnson by 13.5% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 19,775 shares of the company’s stock valued at $3,205,000 after acquiring an additional 2,350 shares in the last quarter. Wrapmanager Inc. increased its holdings in Johnson & Johnson by 18.0% during the 3rd quarter. Wrapmanager Inc. now owns 17,017 shares of the company’s stock worth $2,758,000 after purchasing an additional 2,601 shares in the last quarter. BIP Wealth LLC raised its stake in shares of Johnson & Johnson by 10.7% in the third quarter. BIP Wealth LLC now owns 7,481 shares of the company’s stock worth $1,212,000 after purchasing an additional 722 shares during the last quarter. Finally, Prospera Financial Services Inc boosted its position in shares of Johnson & Johnson by 17.5% during the third quarter. Prospera Financial Services Inc now owns 110,265 shares of the company’s stock valued at $17,881,000 after buying an additional 16,428 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Guggenheim increased their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Citigroup boosted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $175.94.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $154.77 on Tuesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The stock has a market capitalization of $372.63 billion, a P/E ratio of 22.40, a P/E/G ratio of 2.74 and a beta of 0.53. The company’s 50-day moving average is $161.11 and its 200 day moving average is $156.16. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the firm earned $2.66 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.